DU
JAZZ icon

Delphia (USA)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Delphia (USA)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,635
Closed -$255K – 355
2022
Q2 		$255K Sell
1,635
-560
-26% -$86.2K 0.18% 217
2022
Q1 		$342K Buy
+2,195
New +$319K 0.26% 144

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Delphia (USA)'s JAZZ Position: Q3 2022 in Review

Delphia (USA) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 1,635 shares — an estimated $255K sold.

Delphia (USA) first reported a position in JAZZ in Q1 2022 and held it in 2 quarters. The position peaked at $342K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

  • Delphia (USA) reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Delphia (USA) sold 1,635 Jazz Pharmaceuticals shares in Q3 2022, an estimated $255K.
  • Delphia (USA) first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Delphia (USA)'s Jazz Pharmaceuticals position peaked at $342K in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.